[HTML] springer.comFull View

[HTML][HTML] Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

M Atefi, B Titz, E Avramis, C Ng, DJL Wong, A Lassen… - Molecular cancer, 2015 - Springer
Background Approximately 20% of melanomas contain a mutation in NRAS. However no
direct inhibitor of NRAS is available. One of the main signaling pathways downstream of …
被引用次数：65 相关文章
[PDF] academia.edu

[PDF][PDF] Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

M Atefi, B Titz, E Avramis, C Ng, DJL Wong, A Lassen… - 2015 - academia.edu
Background: Approximately 20% of melanomas contain a mutation in NRAS. However no
direct inhibitor of NRAS is available. One of the main signaling pathways downstream of …
[PDF] core.ac.uk

[PDF][PDF] Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

M Atefi, B Titz, E Avramis, C Ng, DJL Wong, A Lassen… - 2015 - core.ac.uk
Background: Approximately 20% of melanomas contain a mutation in NRAS. However no
direct inhibitor of NRAS is available. One of the main signaling pathways downstream of …
[HTML] europepmc.org

[HTML][HTML] Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.

M Atefi, B Titz, E Avramis, C Ng, DJ Wong… - Molecular …, 2015 - europepmc.org
Background Approximately 20% of melanomas contain a mutation in NRAS. However no
direct inhibitor of NRAS is available. One of the main signaling pathways downstream of …
[PDF] psu.edu

[PDF][PDF] Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

M Atefi, B Titz, E Avramis, C Ng, DJL Wong, A Lassen… - 2015 - Citeseer
Background: Approximately 20% of melanomas contain a mutation in NRAS. However no
direct inhibitor of NRAS is available. One of the main signaling pathways downstream of …
[PDF] researchgate.net

[PDF][PDF] Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

M Atefi, B Titz, E Avramis, C Ng, DJL Wong, A Lassen… - 2015 - researchgate.net
Background: Approximately 20% of melanomas contain a mutation in NRAS. However no
direct inhibitor of NRAS is available. One of the main signaling pathways downstream of …
[PDF] d-nb.info

[PDF][PDF] Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

M Atefi, B Titz, E Avramis, C Ng, DJL Wong, A Lassen… - 2015 - d-nb.info
Background: Approximately 20% of melanomas contain a mutation in NRAS. However no
direct inhibitor of NRAS is available. One of the main signaling pathways downstream of …
[HTML] nih.gov

[HTML][HTML] Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

M Atefi, B Titz, E Avramis, C Ng, DJL Wong… - Molecular …, 2015 - ncbi.nlm.nih.gov
Background Approximately 20% of melanomas contain a mutation in NRAS. However no
direct inhibitor of NRAS is available. One of the main signaling pathways downstream of …

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

M Atefi, B Titz, E Avramis, C Ng… - Molecular …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Approximately 20% of melanomas contain a mutation in NRAS. However no
direct inhibitor of NRAS is available. One of the main signaling pathways downstream of …

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

M Atefi, B Titz, E Avramis, C Ng, DJL Wong… - Molecular …, 2015 - escholarship.org
BackgroundApproximately 20% of melanomas contain a mutation in NRAS. However no
direct inhibitor of NRAS is available. One of the main signaling pathways downstream of …